Read Larry Connors' blog – Short Term Trading Strategies
On this day, the third largest generic and specialty pharmaceuticals company in the world, Mylan Inc., officially takes root in Canada with the launch of Mylan Pharmaceuticals ULC. The Pittsburgh-based company made its entrance into the country via the purchase of Merck KGaA's generics business, which included Genpharm, one of Canada's top generic pharmaceuticals companies. Now, two years after the acquisition, a new corporate entity has emerged and is embarking on a bold program to introduce Mylan and the benefits it will offer to the domestic health care industry.
"It is with great pride that we introduce the Mylan brand in Canada," said Mylan Chairman and CEO Robert J. Coury. "Mylan has been built on a foundation of exceptional customer service and a passionate commitment to the highest of quality standards. We look forward to providing a broader portfolio of more affordable, high quality pharmaceuticals to patients, pharmacists and physicians in the Canadian pharmaceutical market. With the scale of our global platform and our local expertise, we believe that we can truly offer unique solutions that can make a substantial difference to the country's health care system."
Mylan's global portfolio currently numbers more than 900 products. The company provides products to customers in more than 140 countries and territories, and employs approximately 15,000 people worldwide. It holds top-five positions in several established markets worldwide and has an exemplary track record of quality spanning over 48 years.
"The past two years have confirmed our aspirations," said Richard M. Guest, president and CEO of Mylan's Canadian operations and a 28-year veteran in the pharmaceutical industry. "We're certain that Mylan's work ethic, drive for innovation and expertise will have a lasting, positive impact on our team and the Canadian health care industry."
Mylan's legacy and proven business model provides a solid foundation on which the Canadian division will be able to deliver high quality affordable medicines to Canadians. The company's vision starts with leading-edge health care, but goes further to provide tailored business solutions for all of the company's partners. Canadian pharmacists will receive customized services and programs aimed at answering their needs in terms of supply, logistics, education and business support.
"Mylan is committed to Canada," Mr. Guest said. "Our facilities and staff will focus solely on the Canadian market with the goal of doubling our portfolio within five years and improving the level of service that consumers and customers currently receive."
Mylan is one of only two global generic pharmaceutical companies that is vertically and horizontally integrated, a benefit that has helped it expand its global footprint and product portfolio. The company's North America division serves as an umbrella for three other subsidiaries: Mylan Pharmaceuticals Inc., a generic manufacturer that brings innovation and reliability to the marketplace, Mylan Technologies Inc., a world leader in transdermal (patch) drug delivery systems, and UDL Laboratories Inc., a world leader in unit dose packaging and blister pack systems.
Headquarters for Mylan Pharmaceuticals ULC are located in Etobicoke, Ontario, which includes a modern packaging facility, state of the art laboratories and a full commercial operation. The company offers products in all major therapeutic categories including cardiovascular, diabetes, mental health and gastrointestinal. Its current portfolio numbers more than 100 products and the company employs approximately 460 people across the country.
About Mylan Inc.
Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates the world's third largest active pharmaceutical ingredient manufacturer; and runs a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.
SOURCE: Mylan Pharmaceuticals ULC
Kathleen Stelmach, Torchia Communications, (416) 341-9929, ext. 227, kathleen@torchiacom.com; Daniel Torchia, Torchia Communications, (416) 341-9929, ext. 223, daniel@torchiacom.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
